Recurrent Pityriasis Versicolor
Conditions
Brief summary
Blood samples will be taken from cases presenting with recurrent tinea versicolor , after confirmation of diagnosis by wood's light and KOH examination, for the detection of gene polymorphism in IL17 A and IL17 F. In addition , serum samples from patients and controls will be tested for 25(OH)2 D3
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* \- Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it. * Patients of both genders. * Age ≥18 years old.
Exclusion criteria
* \- Patients with other cutaneous diseases. * Patient's having dandruff (scaly scalp) even if not symptomatizing. * Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects. * Patients with autoimmune diseases. * Patients with immunodeficiency diseases. * Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IL 17A gene polymorphism | 6months-1 year | IL 17A |
| IL 17 F gene polymorphism | 6months-1 year | IL 17 F |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vitamin D | 6months-1 year | Serum 25(OH)2 D3 |
Countries
Egypt